Beside its prognostic value, the mutational status of IGHV genes also represents a predictive biomarker, since CLL patients with mutated IGHV genes and devoid of TP53 abnormalities may still benefit from chemoimmunotherapy (CIT), which is otherwise considered a suboptimal treatment for IGHV-unmutated patients [13,14,15]. Here, TP53 is linked to B-cell chronic lymphocytic leukemia.